A Phase I Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 in HIV-Infected Patients.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 728 T (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 24 Jul 2013 Full results are expected to be reported by the end of 2013, according to a Sangamo BioSciences media release.
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.